Bruker Corporation (NASDAQ: BRKRP) Stock Competitors & Peer Comparison
See BRKRP's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Medical - Devices Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for BRKRP and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| BRKRP | $446.63 | +4.68% | 9.3B | 244.34 | $1.84 | +0.33% |
| ABT | $109.93 | -3.23% | 190.3B | 21.10 | $5.21 | +2.28% |
| BSX-PA | $122.18 | +2.37% | 175.4B | 230.53 | $0.53 | N/A |
| MDT | $101.80 | -2.90% | 130.2B | 18.41 | $5.53 | +2.81% |
| SYK | $325.87 | -2.75% | 124.1B | 24.34 | $13.39 | +1.09% |
| BSX | $42.75 | -4.23% | 62B | 13.79 | $3.10 | N/A |
| EW | $102.14 | +1.31% | 58.9B | 37.82 | $2.70 | N/A |
| GEHC | $82.38 | -1.64% | 37.2B | 16.81 | $4.90 | +0.18% |
| PHG | $30.35 | -0.52% | 29.7B | 17.34 | $1.75 | +3.27% |
| DXCM | $79.41 | -5.98% | 29.6B | 31.14 | $2.55 | N/A |
Stock Comparison
Abbott Laboratories (NYSE: ABT)
BRKRP vs ABT Comparison November 2026
Bruker Corporation (NASDAQ: BRKRP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BRKRP stands at 9.3B. In comparison, ABT has a market cap of 190.3B. Regarding current trading prices, BRKRP is priced at $446.63 on the NASDAQ, while ABT trades at $109.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BRKRP currently has a P/E ratio of 244.34, whereas ABT's P/E ratio is 21.10. In terms of profitability, BRKRP's ROE is -0.05%, compared to ABT's ROE of +0.09%. Regarding short-term risk, BRKRP is more volatile compared to ABT. This indicates higher risk in terms of short-term price fluctuations for BRKRP.Check ABT's competition here
Boston Scientific Corporation (NYSE: BSX-PA)
BRKRP vs BSX-PA Comparison November 2026
Bruker Corporation (NASDAQ: BRKRP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BRKRP stands at 9.3B. In comparison, BSX-PA has a market cap of 175.4B. Regarding current trading prices, BRKRP is priced at $446.63 on the NASDAQ, while BSX-PA trades at $122.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BRKRP currently has a P/E ratio of 244.34, whereas BSX-PA's P/E ratio is 230.53. In terms of profitability, BRKRP's ROE is -0.05%, compared to BSX-PA's ROE of +0.14%. Regarding short-term risk, BRKRP is less volatile compared to BSX-PA. This indicates lower risk in terms of short-term price fluctuations for BRKRP.Check BSX-PA's competition here
Medtronic Plc (NYSE: MDT)
BRKRP vs MDT Comparison November 2026
Bruker Corporation (NASDAQ: BRKRP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BRKRP stands at 9.3B. In comparison, MDT has a market cap of 130.2B. Regarding current trading prices, BRKRP is priced at $446.63 on the NASDAQ, while MDT trades at $101.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BRKRP currently has a P/E ratio of 244.34, whereas MDT's P/E ratio is 18.41. In terms of profitability, BRKRP's ROE is -0.05%, compared to MDT's ROE of +0.11%. Regarding short-term risk, BRKRP is less volatile compared to MDT. This indicates lower risk in terms of short-term price fluctuations for BRKRP.Check MDT's competition here
Stryker Corporation (NYSE: SYK)
BRKRP vs SYK Comparison November 2026
Bruker Corporation (NASDAQ: BRKRP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BRKRP stands at 9.3B. In comparison, SYK has a market cap of 124.1B. Regarding current trading prices, BRKRP is priced at $446.63 on the NASDAQ, while SYK trades at $325.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BRKRP currently has a P/E ratio of 244.34, whereas SYK's P/E ratio is 24.34. In terms of profitability, BRKRP's ROE is -0.05%, compared to SYK's ROE of +0.16%. Regarding short-term risk, BRKRP is more volatile compared to SYK. This indicates higher risk in terms of short-term price fluctuations for BRKRP.Check SYK's competition here
Boston Scientific Corporation (NYSE: BSX)
BRKRP vs BSX Comparison November 2026
Bruker Corporation (NASDAQ: BRKRP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BRKRP stands at 9.3B. In comparison, BSX has a market cap of 62B. Regarding current trading prices, BRKRP is priced at $446.63 on the NASDAQ, while BSX trades at $42.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BRKRP currently has a P/E ratio of 244.34, whereas BSX's P/E ratio is 13.79. In terms of profitability, BRKRP's ROE is -0.05%, compared to BSX's ROE of +0.14%. Regarding short-term risk, BRKRP is less volatile compared to BSX. This indicates lower risk in terms of short-term price fluctuations for BRKRP.Check BSX's competition here
Edwards Lifesciences Corporation (NYSE: EW)
BRKRP vs EW Comparison November 2026
Bruker Corporation (NASDAQ: BRKRP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BRKRP stands at 9.3B. In comparison, EW has a market cap of 58.9B. Regarding current trading prices, BRKRP is priced at $446.63 on the NASDAQ, while EW trades at $102.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BRKRP currently has a P/E ratio of 244.34, whereas EW's P/E ratio is 37.82. In terms of profitability, BRKRP's ROE is -0.05%, compared to EW's ROE of +0.10%. Regarding short-term risk, BRKRP is less volatile compared to EW. This indicates lower risk in terms of short-term price fluctuations for BRKRP.Check EW's competition here
GE HealthCare Technologies Inc. (NASDAQ: GEHC)
BRKRP vs GEHC Comparison November 2026
Bruker Corporation (NASDAQ: BRKRP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BRKRP stands at 9.3B. In comparison, GEHC has a market cap of 37.2B. Regarding current trading prices, BRKRP is priced at $446.63 on the NASDAQ, while GEHC trades at $82.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BRKRP currently has a P/E ratio of 244.34, whereas GEHC's P/E ratio is 16.81. In terms of profitability, BRKRP's ROE is -0.05%, compared to GEHC's ROE of +0.16%. Regarding short-term risk, BRKRP is less volatile compared to GEHC. This indicates lower risk in terms of short-term price fluctuations for BRKRP.Check GEHC's competition here
Koninklijke Philips N.V. (NYSE: PHG)
BRKRP vs PHG Comparison November 2026
Bruker Corporation (NASDAQ: BRKRP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BRKRP stands at 9.3B. In comparison, PHG has a market cap of 29.7B. Regarding current trading prices, BRKRP is priced at $446.63 on the NASDAQ, while PHG trades at $30.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BRKRP currently has a P/E ratio of 244.34, whereas PHG's P/E ratio is 17.34. In terms of profitability, BRKRP's ROE is -0.05%, compared to PHG's ROE of +0.08%. Regarding short-term risk, BRKRP is less volatile compared to PHG. This indicates lower risk in terms of short-term price fluctuations for BRKRP.Check PHG's competition here
DexCom, Inc. (NASDAQ: DXCM)
BRKRP vs DXCM Comparison November 2026
Bruker Corporation (NASDAQ: BRKRP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BRKRP stands at 9.3B. In comparison, DXCM has a market cap of 29.6B. Regarding current trading prices, BRKRP is priced at $446.63 on the NASDAQ, while DXCM trades at $79.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BRKRP currently has a P/E ratio of 244.34, whereas DXCM's P/E ratio is 31.14. In terms of profitability, BRKRP's ROE is -0.05%, compared to DXCM's ROE of +0.37%. Regarding short-term risk, BRKRP is less volatile compared to DXCM. This indicates lower risk in terms of short-term price fluctuations for BRKRP.Check DXCM's competition here
Zimmer Biomet Holdings, Inc. (NYSE: ZBH)
BRKRP vs ZBH Comparison November 2026
Bruker Corporation (NASDAQ: BRKRP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BRKRP stands at 9.3B. In comparison, ZBH has a market cap of 20.1B. Regarding current trading prices, BRKRP is priced at $446.63 on the NASDAQ, while ZBH trades at $105.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BRKRP currently has a P/E ratio of 244.34, whereas ZBH's P/E ratio is 12.45. In terms of profitability, BRKRP's ROE is -0.05%, compared to ZBH's ROE of +0.06%. Regarding short-term risk, BRKRP is less volatile compared to ZBH. This indicates lower risk in terms of short-term price fluctuations for BRKRP.Check ZBH's competition here
Abiomed, Inc. (NASDAQ: ABMD)
BRKRP vs ABMD Comparison November 2026
Bruker Corporation (NASDAQ: BRKRP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BRKRP stands at 9.3B. In comparison, ABMD has a market cap of 17.2B. Regarding current trading prices, BRKRP is priced at $446.63 on the NASDAQ, while ABMD trades at $381.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BRKRP currently has a P/E ratio of 244.34, whereas ABMD's P/E ratio is 65.36. In terms of profitability, BRKRP's ROE is -0.05%, compared to ABMD's ROE of +0.10%. Regarding short-term risk, BRKRP is more volatile compared to ABMD. This indicates higher risk in terms of short-term price fluctuations for BRKRP.Check ABMD's competition here
Glaukos Corporation (NYSE: GKOS)
BRKRP vs GKOS Comparison November 2026
Bruker Corporation (NASDAQ: BRKRP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BRKRP stands at 9.3B. In comparison, GKOS has a market cap of 13.3B. Regarding current trading prices, BRKRP is priced at $446.63 on the NASDAQ, while GKOS trades at $224.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BRKRP currently has a P/E ratio of 244.34, whereas GKOS's P/E ratio is -260.83. In terms of profitability, BRKRP's ROE is -0.05%, compared to GKOS's ROE of -0.25%. Regarding short-term risk, BRKRP is less volatile compared to GKOS. This indicates lower risk in terms of short-term price fluctuations for BRKRP.Check GKOS's competition here
Smith & Nephew plc (NYSE: SNN)
BRKRP vs SNN Comparison November 2026
Bruker Corporation (NASDAQ: BRKRP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BRKRP stands at 9.3B. In comparison, SNN has a market cap of 13.1B. Regarding current trading prices, BRKRP is priced at $446.63 on the NASDAQ, while SNN trades at $31.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BRKRP currently has a P/E ratio of 244.34, whereas SNN's P/E ratio is 21.03. In terms of profitability, BRKRP's ROE is -0.05%, compared to SNN's ROE of +0.12%. Regarding short-term risk, BRKRP is more volatile compared to SNN. This indicates higher risk in terms of short-term price fluctuations for BRKRP.Check SNN's competition here
Penumbra, Inc. (NYSE: PEN)
BRKRP vs PEN Comparison November 2026
Bruker Corporation (NASDAQ: BRKRP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BRKRP stands at 9.3B. In comparison, PEN has a market cap of 12.6B. Regarding current trading prices, BRKRP is priced at $446.63 on the NASDAQ, while PEN trades at $319.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BRKRP currently has a P/E ratio of 244.34, whereas PEN's P/E ratio is 83.37. In terms of profitability, BRKRP's ROE is -0.05%, compared to PEN's ROE of +0.10%. Regarding short-term risk, BRKRP is more volatile compared to PEN. This indicates higher risk in terms of short-term price fluctuations for BRKRP.Check PEN's competition here
ShockWave Medical, Inc. (NASDAQ: SWAV)
BRKRP vs SWAV Comparison November 2026
Bruker Corporation (NASDAQ: BRKRP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BRKRP stands at 9.3B. In comparison, SWAV has a market cap of 12.6B. Regarding current trading prices, BRKRP is priced at $446.63 on the NASDAQ, while SWAV trades at $334.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BRKRP currently has a P/E ratio of 244.34, whereas SWAV's P/E ratio is 78.76. In terms of profitability, BRKRP's ROE is -0.05%, compared to SWAV's ROE of +0.25%. Regarding short-term risk, BRKRP is more volatile compared to SWAV. This indicates higher risk in terms of short-term price fluctuations for BRKRP.Check SWAV's competition here
Align Technology, Inc. (NASDAQ: ALGN)
BRKRP vs ALGN Comparison November 2026
Bruker Corporation (NASDAQ: BRKRP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BRKRP stands at 9.3B. In comparison, ALGN has a market cap of 11.8B. Regarding current trading prices, BRKRP is priced at $446.63 on the NASDAQ, while ALGN trades at $166.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BRKRP currently has a P/E ratio of 244.34, whereas ALGN's P/E ratio is 15.14. In terms of profitability, BRKRP's ROE is -0.05%, compared to ALGN's ROE of +0.12%. Regarding short-term risk, BRKRP is less volatile compared to ALGN. This indicates lower risk in terms of short-term price fluctuations for BRKRP.Check ALGN's competition here
Bio-Rad Laboratories, Inc. (NYSE: BIO)
BRKRP vs BIO Comparison November 2026
Bruker Corporation (NASDAQ: BRKRP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BRKRP stands at 9.3B. In comparison, BIO has a market cap of 10.2B. Regarding current trading prices, BRKRP is priced at $446.63 on the NASDAQ, while BIO trades at $381.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BRKRP currently has a P/E ratio of 244.34, whereas BIO's P/E ratio is 41.12. In terms of profitability, BRKRP's ROE is -0.05%, compared to BIO's ROE of +0.14%. Regarding short-term risk, BRKRP is less volatile compared to BIO. This indicates lower risk in terms of short-term price fluctuations for BRKRP.Check BIO's competition here
Insulet Corp. (NASDAQ: PODD)
BRKRP vs PODD Comparison November 2026
Bruker Corporation (NASDAQ: BRKRP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BRKRP stands at 9.3B. In comparison, PODD has a market cap of 10.2B. Regarding current trading prices, BRKRP is priced at $446.63 on the NASDAQ, while PODD trades at $146.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BRKRP currently has a P/E ratio of 244.34, whereas PODD's P/E ratio is 24.96. In terms of profitability, BRKRP's ROE is -0.05%, compared to PODD's ROE of +0.29%. Regarding short-term risk, BRKRP is less volatile compared to PODD. This indicates lower risk in terms of short-term price fluctuations for BRKRP.Check PODD's competition here
Bio-Rad Laboratories, Inc. (NYSE: BIO-B)
BRKRP vs BIO-B Comparison November 2026
Bruker Corporation (NASDAQ: BRKRP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BRKRP stands at 9.3B. In comparison, BIO-B has a market cap of 9.9B. Regarding current trading prices, BRKRP is priced at $446.63 on the NASDAQ, while BIO-B trades at $374.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BRKRP currently has a P/E ratio of 244.34, whereas BIO-B's P/E ratio is -65.97. In terms of profitability, BRKRP's ROE is -0.05%, compared to BIO-B's ROE of +0.14%. Regarding short-term risk, BRKRP is less volatile compared to BIO-B. This indicates lower risk in terms of short-term price fluctuations for BRKRP.Check BIO-B's competition here
Globus Medical, Inc. (NYSE: GMED)
BRKRP vs GMED Comparison November 2026
Bruker Corporation (NASDAQ: BRKRP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BRKRP stands at 9.3B. In comparison, GMED has a market cap of 9.5B. Regarding current trading prices, BRKRP is priced at $446.63 on the NASDAQ, while GMED trades at $71.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BRKRP currently has a P/E ratio of 244.34, whereas GMED's P/E ratio is 16.00. In terms of profitability, BRKRP's ROE is -0.05%, compared to GMED's ROE of +0.12%. Regarding short-term risk, BRKRP is less volatile compared to GMED. This indicates lower risk in terms of short-term price fluctuations for BRKRP.Check GMED's competition here
Masimo Corporation (NASDAQ: MASI)
BRKRP vs MASI Comparison November 2026
Bruker Corporation (NASDAQ: BRKRP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BRKRP stands at 9.3B. In comparison, MASI has a market cap of 9.4B. Regarding current trading prices, BRKRP is priced at $446.63 on the NASDAQ, while MASI trades at $179.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BRKRP currently has a P/E ratio of 244.34, whereas MASI's P/E ratio is 44.43. In terms of profitability, BRKRP's ROE is -0.05%, compared to MASI's ROE of +0.09%. Regarding short-term risk, BRKRP is more volatile compared to MASI. This indicates higher risk in terms of short-term price fluctuations for BRKRP.Check MASI's competition here
Bruker Corporation (NASDAQ: BRKR)
BRKRP vs BRKR Comparison November 2026
Bruker Corporation (NASDAQ: BRKRP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BRKRP stands at 9.3B. In comparison, BRKR has a market cap of 9.3B. Regarding current trading prices, BRKRP is priced at $446.63 on the NASDAQ, while BRKR trades at $61.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BRKRP currently has a P/E ratio of 244.34, whereas BRKR's P/E ratio is 30.81. In terms of profitability, BRKRP's ROE is -0.05%, compared to BRKR's ROE of -0.05%. Regarding short-term risk, BRKRP is less volatile compared to BRKR. This indicates lower risk in terms of short-term price fluctuations for BRKRP.Check BRKR's competition here
Haemonetics Corporation (NYSE: HAE)
BRKRP vs HAE Comparison November 2026
Bruker Corporation (NASDAQ: BRKRP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BRKRP stands at 9.3B. In comparison, HAE has a market cap of 5.5B. Regarding current trading prices, BRKRP is priced at $446.63 on the NASDAQ, while HAE trades at $119.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BRKRP currently has a P/E ratio of 244.34, whereas HAE's P/E ratio is 23.93. In terms of profitability, BRKRP's ROE is -0.05%, compared to HAE's ROE of +0.12%. Regarding short-term risk, BRKRP is less volatile compared to HAE. This indicates lower risk in terms of short-term price fluctuations for BRKRP.Check HAE's competition here
LivaNova PLC (NASDAQ: LIVN)
BRKRP vs LIVN Comparison November 2026
Bruker Corporation (NASDAQ: BRKRP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BRKRP stands at 9.3B. In comparison, LIVN has a market cap of 4.9B. Regarding current trading prices, BRKRP is priced at $446.63 on the NASDAQ, while LIVN trades at $89.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BRKRP currently has a P/E ratio of 244.34, whereas LIVN's P/E ratio is 21.37. In terms of profitability, BRKRP's ROE is -0.05%, compared to LIVN's ROE of +0.15%. Regarding short-term risk, BRKRP is less volatile compared to LIVN. This indicates lower risk in terms of short-term price fluctuations for BRKRP.Check LIVN's competition here
Inari Medical, Inc. (NASDAQ: NARI)
BRKRP vs NARI Comparison November 2026
Bruker Corporation (NASDAQ: BRKRP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BRKRP stands at 9.3B. In comparison, NARI has a market cap of 4.7B. Regarding current trading prices, BRKRP is priced at $446.63 on the NASDAQ, while NARI trades at $79.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BRKRP currently has a P/E ratio of 244.34, whereas NARI's P/E ratio is -59.24. In terms of profitability, BRKRP's ROE is -0.05%, compared to NARI's ROE of -0.00%. Regarding short-term risk, BRKRP is more volatile compared to NARI. This indicates higher risk in terms of short-term price fluctuations for BRKRP.Check NARI's competition here
Integer Holdings Corporation (NYSE: ITGR)
BRKRP vs ITGR Comparison November 2026
Bruker Corporation (NASDAQ: BRKRP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BRKRP stands at 9.3B. In comparison, ITGR has a market cap of 4.3B. Regarding current trading prices, BRKRP is priced at $446.63 on the NASDAQ, while ITGR trades at $126.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BRKRP currently has a P/E ratio of 244.34, whereas ITGR's P/E ratio is 19.94. In terms of profitability, BRKRP's ROE is -0.05%, compared to ITGR's ROE of +0.06%. Regarding short-term risk, BRKRP is more volatile compared to ITGR. This indicates higher risk in terms of short-term price fluctuations for BRKRP.Check ITGR's competition here
TransMedics Group, Inc. (NASDAQ: TMDX)
BRKRP vs TMDX Comparison November 2026
Bruker Corporation (NASDAQ: BRKRP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BRKRP stands at 9.3B. In comparison, TMDX has a market cap of 3.1B. Regarding current trading prices, BRKRP is priced at $446.63 on the NASDAQ, while TMDX trades at $88.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BRKRP currently has a P/E ratio of 244.34, whereas TMDX's P/E ratio is 44.77. In terms of profitability, BRKRP's ROE is -0.05%, compared to TMDX's ROE of +0.28%. Regarding short-term risk, BRKRP is less volatile compared to TMDX. This indicates lower risk in terms of short-term price fluctuations for BRKRP.Check TMDX's competition here
AxoGen, Inc. (NASDAQ: AXGN)
BRKRP vs AXGN Comparison November 2026
Bruker Corporation (NASDAQ: BRKRP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BRKRP stands at 9.3B. In comparison, AXGN has a market cap of 3B. Regarding current trading prices, BRKRP is priced at $446.63 on the NASDAQ, while AXGN trades at $50.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BRKRP currently has a P/E ratio of 244.34, whereas AXGN's P/E ratio is 131.53. In terms of profitability, BRKRP's ROE is -0.05%, compared to AXGN's ROE of -0.11%. Regarding short-term risk, BRKRP is less volatile compared to AXGN. This indicates lower risk in terms of short-term price fluctuations for BRKRP.Check AXGN's competition here
iRhythm Technologies, Inc. (NASDAQ: IRTC)
BRKRP vs IRTC Comparison November 2026
Bruker Corporation (NASDAQ: BRKRP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BRKRP stands at 9.3B. In comparison, IRTC has a market cap of 3B. Regarding current trading prices, BRKRP is priced at $446.63 on the NASDAQ, while IRTC trades at $90.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BRKRP currently has a P/E ratio of 244.34, whereas IRTC's P/E ratio is -209.53. In terms of profitability, BRKRP's ROE is -0.05%, compared to IRTC's ROE of -0.23%. Regarding short-term risk, BRKRP is less volatile compared to IRTC. This indicates lower risk in terms of short-term price fluctuations for BRKRP.Check IRTC's competition here
Neogen Corporation (NASDAQ: NEOG)
BRKRP vs NEOG Comparison November 2026
Bruker Corporation (NASDAQ: BRKRP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BRKRP stands at 9.3B. In comparison, NEOG has a market cap of 2.6B. Regarding current trading prices, BRKRP is priced at $446.63 on the NASDAQ, while NEOG trades at $11.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BRKRP currently has a P/E ratio of 244.34, whereas NEOG's P/E ratio is 42.00. In terms of profitability, BRKRP's ROE is -0.05%, compared to NEOG's ROE of -0.03%. Regarding short-term risk, BRKRP is less volatile compared to NEOG. This indicates lower risk in terms of short-term price fluctuations for BRKRP.Check NEOG's competition here
UFP Technologies, Inc. (NASDAQ: UFPT)
BRKRP vs UFPT Comparison November 2026
Bruker Corporation (NASDAQ: BRKRP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BRKRP stands at 9.3B. In comparison, UFPT has a market cap of 2.3B. Regarding current trading prices, BRKRP is priced at $446.63 on the NASDAQ, while UFPT trades at $303.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BRKRP currently has a P/E ratio of 244.34, whereas UFPT's P/E ratio is 30.94. In terms of profitability, BRKRP's ROE is -0.05%, compared to UFPT's ROE of +0.17%. Regarding short-term risk, BRKRP is less volatile compared to UFPT. This indicates lower risk in terms of short-term price fluctuations for BRKRP.Check UFPT's competition here
NuVasive, Inc. (NASDAQ: NUVA)
BRKRP vs NUVA Comparison November 2026
Bruker Corporation (NASDAQ: BRKRP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BRKRP stands at 9.3B. In comparison, NUVA has a market cap of 2.1B. Regarding current trading prices, BRKRP is priced at $446.63 on the NASDAQ, while NUVA trades at $39.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BRKRP currently has a P/E ratio of 244.34, whereas NUVA's P/E ratio is 75.00. In terms of profitability, BRKRP's ROE is -0.05%, compared to NUVA's ROE of +0.05%. Regarding short-term risk, BRKRP is less volatile compared to NUVA. This indicates lower risk in terms of short-term price fluctuations for BRKRP.Check NUVA's competition here
Establishment Labs Holdings Inc. (NASDAQ: ESTA)
BRKRP vs ESTA Comparison November 2026
Bruker Corporation (NASDAQ: BRKRP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BRKRP stands at 9.3B. In comparison, ESTA has a market cap of 2B. Regarding current trading prices, BRKRP is priced at $446.63 on the NASDAQ, while ESTA trades at $67.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BRKRP currently has a P/E ratio of 244.34, whereas ESTA's P/E ratio is -53.24. In terms of profitability, BRKRP's ROE is -0.05%, compared to ESTA's ROE of -2.04%. Regarding short-term risk, BRKRP is less volatile compared to ESTA. This indicates lower risk in terms of short-term price fluctuations for BRKRP.Check ESTA's competition here
Inspire Medical Systems, Inc. (NYSE: INSP)
BRKRP vs INSP Comparison November 2026
Bruker Corporation (NASDAQ: BRKRP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BRKRP stands at 9.3B. In comparison, INSP has a market cap of 1.9B. Regarding current trading prices, BRKRP is priced at $446.63 on the NASDAQ, while INSP trades at $63.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BRKRP currently has a P/E ratio of 244.34, whereas INSP's P/E ratio is 28.18. In terms of profitability, BRKRP's ROE is -0.05%, compared to INSP's ROE of +0.12%. Regarding short-term risk, BRKRP is less volatile compared to INSP. This indicates lower risk in terms of short-term price fluctuations for BRKRP.Check INSP's competition here
Butterfly Network, Inc. (NYSE: BFLY)
BRKRP vs BFLY Comparison November 2026
Bruker Corporation (NASDAQ: BRKRP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BRKRP stands at 9.3B. In comparison, BFLY has a market cap of 1.7B. Regarding current trading prices, BRKRP is priced at $446.63 on the NASDAQ, while BFLY trades at $6.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BRKRP currently has a P/E ratio of 244.34, whereas BFLY's P/E ratio is -26.52. In terms of profitability, BRKRP's ROE is -0.05%, compared to BFLY's ROE of -0.28%. Regarding short-term risk, BRKRP is less volatile compared to BFLY. This indicates lower risk in terms of short-term price fluctuations for BRKRP.Check BFLY's competition here
Enovis Corporation (NYSE: ENOV)
BRKRP vs ENOV Comparison November 2026
Bruker Corporation (NASDAQ: BRKRP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BRKRP stands at 9.3B. In comparison, ENOV has a market cap of 1.6B. Regarding current trading prices, BRKRP is priced at $446.63 on the NASDAQ, while ENOV trades at $27.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BRKRP currently has a P/E ratio of 244.34, whereas ENOV's P/E ratio is 7.77. In terms of profitability, BRKRP's ROE is -0.05%, compared to ENOV's ROE of -0.36%. Regarding short-term risk, BRKRP is less volatile compared to ENOV. This indicates lower risk in terms of short-term price fluctuations for BRKRP.Check ENOV's competition here
Novocure Ltd (NASDAQ: NVCR)
BRKRP vs NVCR Comparison November 2026
Bruker Corporation (NASDAQ: BRKRP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BRKRP stands at 9.3B. In comparison, NVCR has a market cap of 1.6B. Regarding current trading prices, BRKRP is priced at $446.63 on the NASDAQ, while NVCR trades at $13.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BRKRP currently has a P/E ratio of 244.34, whereas NVCR's P/E ratio is -12.52. In terms of profitability, BRKRP's ROE is -0.05%, compared to NVCR's ROE of -0.36%. Regarding short-term risk, BRKRP is less volatile compared to NVCR. This indicates lower risk in terms of short-term price fluctuations for BRKRP.Check NVCR's competition here
CONMED Corporation (NYSE: CNMD)
BRKRP vs CNMD Comparison November 2026
Bruker Corporation (NASDAQ: BRKRP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BRKRP stands at 9.3B. In comparison, CNMD has a market cap of 1.5B. Regarding current trading prices, BRKRP is priced at $446.63 on the NASDAQ, while CNMD trades at $51.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BRKRP currently has a P/E ratio of 244.34, whereas CNMD's P/E ratio is 11.32. In terms of profitability, BRKRP's ROE is -0.05%, compared to CNMD's ROE of +0.07%. Regarding short-term risk, BRKRP is less volatile compared to CNMD. This indicates lower risk in terms of short-term price fluctuations for BRKRP.Check CNMD's competition here
Heska Corporation (NASDAQ: HSKA)
BRKRP vs HSKA Comparison November 2026
Bruker Corporation (NASDAQ: BRKRP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BRKRP stands at 9.3B. In comparison, HSKA has a market cap of 1.3B. Regarding current trading prices, BRKRP is priced at $446.63 on the NASDAQ, while HSKA trades at $119.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BRKRP currently has a P/E ratio of 244.34, whereas HSKA's P/E ratio is -62.49. In terms of profitability, BRKRP's ROE is -0.05%, compared to HSKA's ROE of -0.04%. Regarding short-term risk, BRKRP is more volatile compared to HSKA. This indicates higher risk in terms of short-term price fluctuations for BRKRP.Check HSKA's competition here
Lumexa Imaging Holdings, Inc. Common Stock (NASDAQ: LMRI)
BRKRP vs LMRI Comparison November 2026
Bruker Corporation (NASDAQ: BRKRP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BRKRP stands at 9.3B. In comparison, LMRI has a market cap of 1.3B. Regarding current trading prices, BRKRP is priced at $446.63 on the NASDAQ, while LMRI trades at $13.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BRKRP currently has a P/E ratio of 244.34, whereas LMRI's P/E ratio is -26.07. In terms of profitability, BRKRP's ROE is -0.05%, compared to LMRI's ROE of -0.06%. Regarding short-term risk, BRKRP is less volatile compared to LMRI. This indicates lower risk in terms of short-term price fluctuations for BRKRP.Check LMRI's competition here
Tandem Diabetes Care, Inc. (NASDAQ: TNDM)
BRKRP vs TNDM Comparison November 2026
Bruker Corporation (NASDAQ: BRKRP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BRKRP stands at 9.3B. In comparison, TNDM has a market cap of 1.2B. Regarding current trading prices, BRKRP is priced at $446.63 on the NASDAQ, while TNDM trades at $16.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BRKRP currently has a P/E ratio of 244.34, whereas TNDM's P/E ratio is -18.18. In terms of profitability, BRKRP's ROE is -0.05%, compared to TNDM's ROE of -0.36%. Regarding short-term risk, BRKRP is less volatile compared to TNDM. This indicates lower risk in terms of short-term price fluctuations for BRKRP.Check TNDM's competition here
PROCEPT BioRobotics Corporation (NASDAQ: PRCT)
BRKRP vs PRCT Comparison November 2026
Bruker Corporation (NASDAQ: BRKRP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BRKRP stands at 9.3B. In comparison, PRCT has a market cap of 1.2B. Regarding current trading prices, BRKRP is priced at $446.63 on the NASDAQ, while PRCT trades at $20.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BRKRP currently has a P/E ratio of 244.34, whereas PRCT's P/E ratio is -10.62. In terms of profitability, BRKRP's ROE is -0.05%, compared to PRCT's ROE of -0.33%. Regarding short-term risk, BRKRP is less volatile compared to PRCT. This indicates lower risk in terms of short-term price fluctuations for BRKRP.Check PRCT's competition here
Avanos Medical, Inc. (NYSE: AVNS)
BRKRP vs AVNS Comparison November 2026
Bruker Corporation (NASDAQ: BRKRP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BRKRP stands at 9.3B. In comparison, AVNS has a market cap of 1.2B. Regarding current trading prices, BRKRP is priced at $446.63 on the NASDAQ, while AVNS trades at $24.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BRKRP currently has a P/E ratio of 244.34, whereas AVNS's P/E ratio is 27.77. In terms of profitability, BRKRP's ROE is -0.05%, compared to AVNS's ROE of -0.09%. Regarding short-term risk, BRKRP is more volatile compared to AVNS. This indicates higher risk in terms of short-term price fluctuations for BRKRP.Check AVNS's competition here
Alphatec Holdings, Inc. (NASDAQ: ATEC)
BRKRP vs ATEC Comparison November 2026
Bruker Corporation (NASDAQ: BRKRP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BRKRP stands at 9.3B. In comparison, ATEC has a market cap of 1.2B. Regarding current trading prices, BRKRP is priced at $446.63 on the NASDAQ, while ATEC trades at $7.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BRKRP currently has a P/E ratio of 244.34, whereas ATEC's P/E ratio is -13.21. In terms of profitability, BRKRP's ROE is -0.05%, compared to ATEC's ROE of -5.47%. Regarding short-term risk, BRKRP is less volatile compared to ATEC. This indicates lower risk in terms of short-term price fluctuations for BRKRP.Check ATEC's competition here
Silk Road Medical, Inc (NASDAQ: SILK)
BRKRP vs SILK Comparison November 2026
Bruker Corporation (NASDAQ: BRKRP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BRKRP stands at 9.3B. In comparison, SILK has a market cap of 1.1B. Regarding current trading prices, BRKRP is priced at $446.63 on the NASDAQ, while SILK trades at $27.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BRKRP currently has a P/E ratio of 244.34, whereas SILK's P/E ratio is -18.96. In terms of profitability, BRKRP's ROE is -0.05%, compared to SILK's ROE of -0.35%. Regarding short-term risk, BRKRP is more volatile compared to SILK. This indicates higher risk in terms of short-term price fluctuations for BRKRP.Check SILK's competition here
Paragon 28, Inc. (NYSE: FNA)
BRKRP vs FNA Comparison November 2026
Bruker Corporation (NASDAQ: BRKRP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BRKRP stands at 9.3B. In comparison, FNA has a market cap of 1.1B. Regarding current trading prices, BRKRP is priced at $446.63 on the NASDAQ, while FNA trades at $13.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BRKRP currently has a P/E ratio of 244.34, whereas FNA's P/E ratio is -19.83. In terms of profitability, BRKRP's ROE is -0.05%, compared to FNA's ROE of -0.35%. Regarding short-term risk, BRKRP is more volatile compared to FNA. This indicates higher risk in terms of short-term price fluctuations for BRKRP.Check FNA's competition here
IRadimed Corporation (NASDAQ: IRMD)
BRKRP vs IRMD Comparison November 2026
Bruker Corporation (NASDAQ: BRKRP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BRKRP stands at 9.3B. In comparison, IRMD has a market cap of 1.1B. Regarding current trading prices, BRKRP is priced at $446.63 on the NASDAQ, while IRMD trades at $86.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BRKRP currently has a P/E ratio of 244.34, whereas IRMD's P/E ratio is 43.16. In terms of profitability, BRKRP's ROE is -0.05%, compared to IRMD's ROE of +0.24%. Regarding short-term risk, BRKRP is less volatile compared to IRMD. This indicates lower risk in terms of short-term price fluctuations for BRKRP.Check IRMD's competition here
SI-BONE, Inc. (NASDAQ: SIBN)
BRKRP vs SIBN Comparison November 2026
Bruker Corporation (NASDAQ: BRKRP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BRKRP stands at 9.3B. In comparison, SIBN has a market cap of 1.1B. Regarding current trading prices, BRKRP is priced at $446.63 on the NASDAQ, while SIBN trades at $24.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BRKRP currently has a P/E ratio of 244.34, whereas SIBN's P/E ratio is -71.29. In terms of profitability, BRKRP's ROE is -0.05%, compared to SIBN's ROE of -0.08%. Regarding short-term risk, BRKRP is less volatile compared to SIBN. This indicates lower risk in terms of short-term price fluctuations for BRKRP.Check SIBN's competition here
Integra LifeSciences Holdings Corporation (NASDAQ: IART)
BRKRP vs IART Comparison November 2026
Bruker Corporation (NASDAQ: BRKRP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BRKRP stands at 9.3B. In comparison, IART has a market cap of 1B. Regarding current trading prices, BRKRP is priced at $446.63 on the NASDAQ, while IART trades at $13.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BRKRP currently has a P/E ratio of 244.34, whereas IART's P/E ratio is 5.69. In terms of profitability, BRKRP's ROE is -0.05%, compared to IART's ROE of +0.01%. Regarding short-term risk, BRKRP is less volatile compared to IART. This indicates lower risk in terms of short-term price fluctuations for BRKRP.Check IART's competition here
CeriBell, Inc. (NASDAQ: CBLL)
BRKRP vs CBLL Comparison November 2026
Bruker Corporation (NASDAQ: BRKRP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BRKRP stands at 9.3B. In comparison, CBLL has a market cap of 1B. Regarding current trading prices, BRKRP is priced at $446.63 on the NASDAQ, while CBLL trades at $26.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BRKRP currently has a P/E ratio of 244.34, whereas CBLL's P/E ratio is -15.12. In terms of profitability, BRKRP's ROE is -0.05%, compared to CBLL's ROE of -0.55%. Regarding short-term risk, BRKRP is less volatile compared to CBLL. This indicates lower risk in terms of short-term price fluctuations for BRKRP.Check CBLL's competition here
AdaptHealth Corp. (NASDAQ: AHCO)
BRKRP vs AHCO Comparison November 2026
Bruker Corporation (NASDAQ: BRKRP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BRKRP stands at 9.3B. In comparison, AHCO has a market cap of 998.7M. Regarding current trading prices, BRKRP is priced at $446.63 on the NASDAQ, while AHCO trades at $7.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BRKRP currently has a P/E ratio of 244.34, whereas AHCO's P/E ratio is 14.95. In terms of profitability, BRKRP's ROE is -0.05%, compared to AHCO's ROE of -0.29%. Regarding short-term risk, BRKRP is less volatile compared to AHCO. This indicates lower risk in terms of short-term price fluctuations for BRKRP.Check AHCO's competition here
Artivion, Inc. (NYSE: AORT)
BRKRP vs AORT Comparison November 2026
Bruker Corporation (NASDAQ: BRKRP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BRKRP stands at 9.3B. In comparison, AORT has a market cap of 985.1M. Regarding current trading prices, BRKRP is priced at $446.63 on the NASDAQ, while AORT trades at $20.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BRKRP currently has a P/E ratio of 244.34, whereas AORT's P/E ratio is 33.67. In terms of profitability, BRKRP's ROE is -0.05%, compared to AORT's ROE of -0.04%. Regarding short-term risk, BRKRP is less volatile compared to AORT. This indicates lower risk in terms of short-term price fluctuations for BRKRP.Check AORT's competition here
Picard Medical, Inc. (AMEX: PMI)
BRKRP vs PMI Comparison November 2026
Bruker Corporation (NASDAQ: BRKRP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BRKRP stands at 9.3B. In comparison, PMI has a market cap of 877.7M. Regarding current trading prices, BRKRP is priced at $446.63 on the NASDAQ, while PMI trades at $9.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BRKRP currently has a P/E ratio of 244.34, whereas PMI's P/E ratio is -7.12. In terms of profitability, BRKRP's ROE is -0.05%, compared to PMI's ROE of -9.31%. Regarding short-term risk, BRKRP is less volatile compared to PMI. This indicates lower risk in terms of short-term price fluctuations for BRKRP.Check PMI's competition here
Cardiovascular Systems, Inc. (NASDAQ: CSII)
BRKRP vs CSII Comparison November 2026
Bruker Corporation (NASDAQ: BRKRP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BRKRP stands at 9.3B. In comparison, CSII has a market cap of 844M. Regarding current trading prices, BRKRP is priced at $446.63 on the NASDAQ, while CSII trades at $20.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BRKRP currently has a P/E ratio of 244.34, whereas CSII's P/E ratio is -20.83. In terms of profitability, BRKRP's ROE is -0.05%, compared to CSII's ROE of -0.14%. Regarding short-term risk, BRKRP is more volatile compared to CSII. This indicates higher risk in terms of short-term price fluctuations for BRKRP.Check CSII's competition here
OrthoPediatrics Corp. (NASDAQ: KIDS)
BRKRP vs KIDS Comparison November 2026
Bruker Corporation (NASDAQ: BRKRP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BRKRP stands at 9.3B. In comparison, KIDS has a market cap of 829.5M. Regarding current trading prices, BRKRP is priced at $446.63 on the NASDAQ, while KIDS trades at $31.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BRKRP currently has a P/E ratio of 244.34, whereas KIDS's P/E ratio is -23.71. In terms of profitability, BRKRP's ROE is -0.05%, compared to KIDS's ROE of -0.10%. Regarding short-term risk, BRKRP is less volatile compared to KIDS. This indicates lower risk in terms of short-term price fluctuations for BRKRP.Check KIDS's competition here
Varex Imaging Corporation (NASDAQ: VREX)
BRKRP vs VREX Comparison November 2026
Bruker Corporation (NASDAQ: BRKRP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BRKRP stands at 9.3B. In comparison, VREX has a market cap of 783.4M. Regarding current trading prices, BRKRP is priced at $446.63 on the NASDAQ, while VREX trades at $18.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BRKRP currently has a P/E ratio of 244.34, whereas VREX's P/E ratio is 19.42. In terms of profitability, BRKRP's ROE is -0.05%, compared to VREX's ROE of +0.05%. Regarding short-term risk, BRKRP is more volatile compared to VREX. This indicates higher risk in terms of short-term price fluctuations for BRKRP.Check VREX's competition here
InMode Ltd. (NASDAQ: INMD)
BRKRP vs INMD Comparison November 2026
Bruker Corporation (NASDAQ: BRKRP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BRKRP stands at 9.3B. In comparison, INMD has a market cap of 767.6M. Regarding current trading prices, BRKRP is priced at $446.63 on the NASDAQ, while INMD trades at $13.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BRKRP currently has a P/E ratio of 244.34, whereas INMD's P/E ratio is 9.26. In terms of profitability, BRKRP's ROE is -0.05%, compared to INMD's ROE of +0.12%. Regarding short-term risk, BRKRP is less volatile compared to INMD. This indicates lower risk in terms of short-term price fluctuations for BRKRP.Check INMD's competition here
Cytek Biosciences, Inc. (NASDAQ: CTKB)
BRKRP vs CTKB Comparison November 2026
Bruker Corporation (NASDAQ: BRKRP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BRKRP stands at 9.3B. In comparison, CTKB has a market cap of 760.4M. Regarding current trading prices, BRKRP is priced at $446.63 on the NASDAQ, while CTKB trades at $5.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BRKRP currently has a P/E ratio of 244.34, whereas CTKB's P/E ratio is -30.99. In terms of profitability, BRKRP's ROE is -0.05%, compared to CTKB's ROE of -0.25%. Regarding short-term risk, BRKRP is less volatile compared to CTKB. This indicates lower risk in terms of short-term price fluctuations for BRKRP.Check CTKB's competition here
Bioventus Inc. (NASDAQ: BVS)
BRKRP vs BVS Comparison November 2026
Bruker Corporation (NASDAQ: BRKRP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BRKRP stands at 9.3B. In comparison, BVS has a market cap of 725.1M. Regarding current trading prices, BRKRP is priced at $446.63 on the NASDAQ, while BVS trades at $10.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BRKRP currently has a P/E ratio of 244.34, whereas BVS's P/E ratio is 13.93. In terms of profitability, BRKRP's ROE is -0.05%, compared to BVS's ROE of +0.27%. Regarding short-term risk, BRKRP is less volatile compared to BVS. This indicates lower risk in terms of short-term price fluctuations for BRKRP.Check BVS's competition here
Beta Bionics, Inc. (NASDAQ: BBNX)
BRKRP vs BBNX Comparison November 2026
Bruker Corporation (NASDAQ: BRKRP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BRKRP stands at 9.3B. In comparison, BBNX has a market cap of 706.8M. Regarding current trading prices, BRKRP is priced at $446.63 on the NASDAQ, while BBNX trades at $15.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BRKRP currently has a P/E ratio of 244.34, whereas BBNX's P/E ratio is -8.54. In terms of profitability, BRKRP's ROE is -0.05%, compared to BBNX's ROE of -0.27%. Regarding short-term risk, BRKRP is less volatile compared to BBNX. This indicates lower risk in terms of short-term price fluctuations for BRKRP.Check BBNX's competition here
Pacific Biosciences of California, Inc. (NASDAQ: PACB)
BRKRP vs PACB Comparison November 2026
Bruker Corporation (NASDAQ: BRKRP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BRKRP stands at 9.3B. In comparison, PACB has a market cap of 700.9M. Regarding current trading prices, BRKRP is priced at $446.63 on the NASDAQ, while PACB trades at $2.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BRKRP currently has a P/E ratio of 244.34, whereas PACB's P/E ratio is -5.50. In terms of profitability, BRKRP's ROE is -0.05%, compared to PACB's ROE of +6.04%. Regarding short-term risk, BRKRP is less volatile compared to PACB. This indicates lower risk in terms of short-term price fluctuations for BRKRP.Check PACB's competition here
Surmodics, Inc. (NASDAQ: SRDX)
BRKRP vs SRDX Comparison November 2026
Bruker Corporation (NASDAQ: BRKRP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BRKRP stands at 9.3B. In comparison, SRDX has a market cap of 614.5M. Regarding current trading prices, BRKRP is priced at $446.63 on the NASDAQ, while SRDX trades at $42.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BRKRP currently has a P/E ratio of 244.34, whereas SRDX's P/E ratio is -34.66. In terms of profitability, BRKRP's ROE is -0.05%, compared to SRDX's ROE of -0.10%. Regarding short-term risk, BRKRP is more volatile compared to SRDX. This indicates higher risk in terms of short-term price fluctuations for BRKRP.Check SRDX's competition here
Tactile Systems Technology, Inc. (NASDAQ: TCMD)
BRKRP vs TCMD Comparison November 2026
Bruker Corporation (NASDAQ: BRKRP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BRKRP stands at 9.3B. In comparison, TCMD has a market cap of 583.1M. Regarding current trading prices, BRKRP is priced at $446.63 on the NASDAQ, while TCMD trades at $26.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BRKRP currently has a P/E ratio of 244.34, whereas TCMD's P/E ratio is 24.10. In terms of profitability, BRKRP's ROE is -0.05%, compared to TCMD's ROE of +0.11%. Regarding short-term risk, BRKRP is less volatile compared to TCMD. This indicates lower risk in terms of short-term price fluctuations for BRKRP.Check TCMD's competition here
Apollo Endosurgery, Inc. (NASDAQ: APEN)
BRKRP vs APEN Comparison November 2026
Bruker Corporation (NASDAQ: BRKRP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BRKRP stands at 9.3B. In comparison, APEN has a market cap of 579.7M. Regarding current trading prices, BRKRP is priced at $446.63 on the NASDAQ, while APEN trades at $10.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BRKRP currently has a P/E ratio of 244.34, whereas APEN's P/E ratio is -9.43. In terms of profitability, BRKRP's ROE is -0.05%, compared to APEN's ROE of -0.85%. Regarding short-term risk, BRKRP is more volatile compared to APEN. This indicates higher risk in terms of short-term price fluctuations for BRKRP.Check APEN's competition here
Sight Sciences, Inc. (NASDAQ: SGHT)
BRKRP vs SGHT Comparison November 2026
Bruker Corporation (NASDAQ: BRKRP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BRKRP stands at 9.3B. In comparison, SGHT has a market cap of 556.4M. Regarding current trading prices, BRKRP is priced at $446.63 on the NASDAQ, while SGHT trades at $10.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BRKRP currently has a P/E ratio of 244.34, whereas SGHT's P/E ratio is -18.04. In terms of profitability, BRKRP's ROE is -0.05%, compared to SGHT's ROE of -0.52%. Regarding short-term risk, BRKRP is less volatile compared to SGHT. This indicates lower risk in terms of short-term price fluctuations for BRKRP.Check SGHT's competition here
Anteris Technologies Global Corp. (NASDAQ: AVR)
BRKRP vs AVR Comparison November 2026
Bruker Corporation (NASDAQ: BRKRP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BRKRP stands at 9.3B. In comparison, AVR has a market cap of 554.1M. Regarding current trading prices, BRKRP is priced at $446.63 on the NASDAQ, while AVR trades at $5.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BRKRP currently has a P/E ratio of 244.34, whereas AVR's P/E ratio is -2.93. In terms of profitability, BRKRP's ROE is -0.05%, compared to AVR's ROE of -0.78%. Regarding short-term risk, BRKRP is less volatile compared to AVR. This indicates lower risk in terms of short-term price fluctuations for BRKRP.Check AVR's competition here
ZimVie Inc. (NASDAQ: ZIMV)
BRKRP vs ZIMV Comparison November 2026
Bruker Corporation (NASDAQ: BRKRP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BRKRP stands at 9.3B. In comparison, ZIMV has a market cap of 535.6M. Regarding current trading prices, BRKRP is priced at $446.63 on the NASDAQ, while ZIMV trades at $18.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BRKRP currently has a P/E ratio of 244.34, whereas ZIMV's P/E ratio is -27.52. In terms of profitability, BRKRP's ROE is -0.05%, compared to ZIMV's ROE of -0.07%. Regarding short-term risk, BRKRP is more volatile compared to ZIMV. This indicates higher risk in terms of short-term price fluctuations for BRKRP.Check ZIMV's competition here
Delcath Systems, Inc. (NASDAQ: DCTH)
BRKRP vs DCTH Comparison November 2026
Bruker Corporation (NASDAQ: BRKRP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BRKRP stands at 9.3B. In comparison, DCTH has a market cap of 518.4M. Regarding current trading prices, BRKRP is priced at $446.63 on the NASDAQ, while DCTH trades at $14.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BRKRP currently has a P/E ratio of 244.34, whereas DCTH's P/E ratio is 1494.00. In terms of profitability, BRKRP's ROE is -0.05%, compared to DCTH's ROE of +0.00%. Regarding short-term risk, BRKRP is less volatile compared to DCTH. This indicates lower risk in terms of short-term price fluctuations for BRKRP.Check DCTH's competition here
Senseonics Holdings, Inc. (NASDAQ: SENS)
BRKRP vs SENS Comparison November 2026
Bruker Corporation (NASDAQ: BRKRP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BRKRP stands at 9.3B. In comparison, SENS has a market cap of 453.7M. Regarding current trading prices, BRKRP is priced at $446.63 on the NASDAQ, while SENS trades at $8.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BRKRP currently has a P/E ratio of 244.34, whereas SENS's P/E ratio is -3.85. In terms of profitability, BRKRP's ROE is -0.05%, compared to SENS's ROE of -1.66%. Regarding short-term risk, BRKRP is less volatile compared to SENS. This indicates lower risk in terms of short-term price fluctuations for BRKRP.Check SENS's competition here
SS Innovations International, Inc. (NASDAQ: SSII)
BRKRP vs SSII Comparison November 2026
Bruker Corporation (NASDAQ: BRKRP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BRKRP stands at 9.3B. In comparison, SSII has a market cap of 430M. Regarding current trading prices, BRKRP is priced at $446.63 on the NASDAQ, while SSII trades at $2.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BRKRP currently has a P/E ratio of 244.34, whereas SSII's P/E ratio is -35.75. In terms of profitability, BRKRP's ROE is -0.05%, compared to SSII's ROE of -0.27%. Regarding short-term risk, BRKRP is less volatile compared to SSII. This indicates lower risk in terms of short-term price fluctuations for BRKRP.Check SSII's competition here
NeuroPace, Inc. (NASDAQ: NPCE)
BRKRP vs NPCE Comparison November 2026
Bruker Corporation (NASDAQ: BRKRP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BRKRP stands at 9.3B. In comparison, NPCE has a market cap of 428.4M. Regarding current trading prices, BRKRP is priced at $446.63 on the NASDAQ, while NPCE trades at $12.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BRKRP currently has a P/E ratio of 244.34, whereas NPCE's P/E ratio is -21.89. In terms of profitability, BRKRP's ROE is -0.05%, compared to NPCE's ROE of -1.20%. Regarding short-term risk, BRKRP is less volatile compared to NPCE. This indicates lower risk in terms of short-term price fluctuations for BRKRP.Check NPCE's competition here
Avita Medical Inc. (NASDAQ: RCEL)
BRKRP vs RCEL Comparison November 2026
Bruker Corporation (NASDAQ: BRKRP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BRKRP stands at 9.3B. In comparison, RCEL has a market cap of 412.4M. Regarding current trading prices, BRKRP is priced at $446.63 on the NASDAQ, while RCEL trades at $16.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BRKRP currently has a P/E ratio of 244.34, whereas RCEL's P/E ratio is -11.53. In terms of profitability, BRKRP's ROE is -0.05%, compared to RCEL's ROE of +1.46%. Regarding short-term risk, BRKRP is less volatile compared to RCEL. This indicates lower risk in terms of short-term price fluctuations for BRKRP.Check RCEL's competition here
Cerus Corporation (NASDAQ: CERS)
BRKRP vs CERS Comparison November 2026
Bruker Corporation (NASDAQ: BRKRP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BRKRP stands at 9.3B. In comparison, CERS has a market cap of 406.9M. Regarding current trading prices, BRKRP is priced at $446.63 on the NASDAQ, while CERS trades at $2.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BRKRP currently has a P/E ratio of 244.34, whereas CERS's P/E ratio is -66.94. In terms of profitability, BRKRP's ROE is -0.05%, compared to CERS's ROE of -0.11%. Regarding short-term risk, BRKRP is less volatile compared to CERS. This indicates lower risk in terms of short-term price fluctuations for BRKRP.Check CERS's competition here
CapsoVision, Inc. (NASDAQ: CV)
BRKRP vs CV Comparison November 2026
Bruker Corporation (NASDAQ: BRKRP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BRKRP stands at 9.3B. In comparison, CV has a market cap of 336M. Regarding current trading prices, BRKRP is priced at $446.63 on the NASDAQ, while CV trades at $6.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BRKRP currently has a P/E ratio of 244.34, whereas CV's P/E ratio is -10.02. In terms of profitability, BRKRP's ROE is -0.05%, compared to CV's ROE of -1.78%. Regarding short-term risk, BRKRP is less volatile compared to CV. This indicates lower risk in terms of short-term price fluctuations for BRKRP.Check CV's competition here
Orthofix Medical Inc. (NASDAQ: OFIX)
BRKRP vs OFIX Comparison November 2026
Bruker Corporation (NASDAQ: BRKRP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BRKRP stands at 9.3B. In comparison, OFIX has a market cap of 317.9M. Regarding current trading prices, BRKRP is priced at $446.63 on the NASDAQ, while OFIX trades at $7.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BRKRP currently has a P/E ratio of 244.34, whereas OFIX's P/E ratio is -5.12. In terms of profitability, BRKRP's ROE is -0.05%, compared to OFIX's ROE of -0.14%. Regarding short-term risk, BRKRP is less volatile compared to OFIX. This indicates lower risk in terms of short-term price fluctuations for BRKRP.Check OFIX's competition here
Semler Scientific, Inc. (NASDAQ: SMLR)
BRKRP vs SMLR Comparison November 2026
Bruker Corporation (NASDAQ: BRKRP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BRKRP stands at 9.3B. In comparison, SMLR has a market cap of 310.7M. Regarding current trading prices, BRKRP is priced at $446.63 on the NASDAQ, while SMLR trades at $20.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BRKRP currently has a P/E ratio of 244.34, whereas SMLR's P/E ratio is 3.92. In terms of profitability, BRKRP's ROE is -0.05%, compared to SMLR's ROE of +0.20%. Regarding short-term risk, BRKRP is more volatile compared to SMLR. This indicates higher risk in terms of short-term price fluctuations for BRKRP.Check SMLR's competition here
ClearPoint Neuro, Inc. (NASDAQ: CLPT)
BRKRP vs CLPT Comparison November 2026
Bruker Corporation (NASDAQ: BRKRP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BRKRP stands at 9.3B. In comparison, CLPT has a market cap of 275.5M. Regarding current trading prices, BRKRP is priced at $446.63 on the NASDAQ, while CLPT trades at $8.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BRKRP currently has a P/E ratio of 244.34, whereas CLPT's P/E ratio is -7.28. In terms of profitability, BRKRP's ROE is -0.05%, compared to CLPT's ROE of -1.70%. Regarding short-term risk, BRKRP is less volatile compared to CLPT. This indicates lower risk in terms of short-term price fluctuations for BRKRP.Check CLPT's competition here
InfuSystem Holdings, Inc. (AMEX: INFU)
BRKRP vs INFU Comparison November 2026
Bruker Corporation (NASDAQ: BRKRP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BRKRP stands at 9.3B. In comparison, INFU has a market cap of 273.5M. Regarding current trading prices, BRKRP is priced at $446.63 on the NASDAQ, while INFU trades at $13.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BRKRP currently has a P/E ratio of 244.34, whereas INFU's P/E ratio is 33.49. In terms of profitability, BRKRP's ROE is -0.05%, compared to INFU's ROE of +0.16%. Regarding short-term risk, BRKRP is less volatile compared to INFU. This indicates lower risk in terms of short-term price fluctuations for BRKRP.Check INFU's competition here
Profound Medical Corp. (NASDAQ: PROF)
BRKRP vs PROF Comparison November 2026
Bruker Corporation (NASDAQ: BRKRP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BRKRP stands at 9.3B. In comparison, PROF has a market cap of 263.8M. Regarding current trading prices, BRKRP is priced at $446.63 on the NASDAQ, while PROF trades at $7.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BRKRP currently has a P/E ratio of 244.34, whereas PROF's P/E ratio is -7.37. In terms of profitability, BRKRP's ROE is -0.05%, compared to PROF's ROE of -0.28%. Regarding short-term risk, BRKRP is less volatile compared to PROF. This indicates lower risk in terms of short-term price fluctuations for BRKRP.Check PROF's competition here
Quantum-Si incorporated (NASDAQ: QSI)
BRKRP vs QSI Comparison November 2026
Bruker Corporation (NASDAQ: BRKRP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BRKRP stands at 9.3B. In comparison, QSI has a market cap of 263.6M. Regarding current trading prices, BRKRP is priced at $446.63 on the NASDAQ, while QSI trades at $1.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BRKRP currently has a P/E ratio of 244.34, whereas QSI's P/E ratio is -2.88. In terms of profitability, BRKRP's ROE is -0.05%, compared to QSI's ROE of -0.45%. Regarding short-term risk, BRKRP is less volatile compared to QSI. This indicates lower risk in terms of short-term price fluctuations for BRKRP.Check QSI's competition here
Treace Medical Concepts, Inc. (NASDAQ: TMCI)
BRKRP vs TMCI Comparison November 2026
Bruker Corporation (NASDAQ: BRKRP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BRKRP stands at 9.3B. In comparison, TMCI has a market cap of 262.7M. Regarding current trading prices, BRKRP is priced at $446.63 on the NASDAQ, while TMCI trades at $4.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BRKRP currently has a P/E ratio of 244.34, whereas TMCI's P/E ratio is -4.30. In terms of profitability, BRKRP's ROE is -0.05%, compared to TMCI's ROE of -0.76%. Regarding short-term risk, BRKRP is less volatile compared to TMCI. This indicates lower risk in terms of short-term price fluctuations for BRKRP.Check TMCI's competition here
Monogram Orthopaedics, Inc. (NASDAQ: MGRM)
BRKRP vs MGRM Comparison November 2026
Bruker Corporation (NASDAQ: BRKRP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BRKRP stands at 9.3B. In comparison, MGRM has a market cap of 243.8M. Regarding current trading prices, BRKRP is priced at $446.63 on the NASDAQ, while MGRM trades at $6.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BRKRP currently has a P/E ratio of 244.34, whereas MGRM's P/E ratio is -12.00. In terms of profitability, BRKRP's ROE is -0.05%, compared to MGRM's ROE of -1.17%. Regarding short-term risk, BRKRP is more volatile compared to MGRM. This indicates higher risk in terms of short-term price fluctuations for BRKRP.Check MGRM's competition here
Nevro Corp. (NYSE: NVRO)
BRKRP vs NVRO Comparison November 2026
Bruker Corporation (NASDAQ: BRKRP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BRKRP stands at 9.3B. In comparison, NVRO has a market cap of 224.1M. Regarding current trading prices, BRKRP is priced at $446.63 on the NASDAQ, while NVRO trades at $5.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BRKRP currently has a P/E ratio of 244.34, whereas NVRO's P/E ratio is -1.91. In terms of profitability, BRKRP's ROE is -0.05%, compared to NVRO's ROE of -0.43%. Regarding short-term risk, BRKRP is more volatile compared to NVRO. This indicates higher risk in terms of short-term price fluctuations for BRKRP.Check NVRO's competition here
Electromed, Inc. (AMEX: ELMD)
BRKRP vs ELMD Comparison November 2026
Bruker Corporation (NASDAQ: BRKRP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BRKRP stands at 9.3B. In comparison, ELMD has a market cap of 223.4M. Regarding current trading prices, BRKRP is priced at $446.63 on the NASDAQ, while ELMD trades at $27.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BRKRP currently has a P/E ratio of 244.34, whereas ELMD's P/E ratio is 20.58. In terms of profitability, BRKRP's ROE is -0.05%, compared to ELMD's ROE of +0.23%. Regarding short-term risk, BRKRP is less volatile compared to ELMD. This indicates lower risk in terms of short-term price fluctuations for BRKRP.Check ELMD's competition here
TriSalus Life Sciences, Inc. (NASDAQ: TLSI)
BRKRP vs TLSI Comparison November 2026
Bruker Corporation (NASDAQ: BRKRP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BRKRP stands at 9.3B. In comparison, TLSI has a market cap of 199.5M. Regarding current trading prices, BRKRP is priced at $446.63 on the NASDAQ, while TLSI trades at $3.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BRKRP currently has a P/E ratio of 244.34, whereas TLSI's P/E ratio is -1.93. In terms of profitability, BRKRP's ROE is -0.05%, compared to TLSI's ROE of +2.74%. Regarding short-term risk, BRKRP is less volatile compared to TLSI. This indicates lower risk in terms of short-term price fluctuations for BRKRP.Check TLSI's competition here
BioSig Technologies, Inc. (NASDAQ: BSGM)
BRKRP vs BSGM Comparison November 2026
Bruker Corporation (NASDAQ: BRKRP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BRKRP stands at 9.3B. In comparison, BSGM has a market cap of 191.1M. Regarding current trading prices, BRKRP is priced at $446.63 on the NASDAQ, while BSGM trades at $6.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BRKRP currently has a P/E ratio of 244.34, whereas BSGM's P/E ratio is -5.81. In terms of profitability, BRKRP's ROE is -0.05%, compared to BSGM's ROE of +6.96%. Regarding short-term risk, BRKRP is less volatile compared to BSGM. This indicates lower risk in terms of short-term price fluctuations for BRKRP.Check BSGM's competition here
RxSight, Inc. (NASDAQ: RXST)
BRKRP vs RXST Comparison November 2026
Bruker Corporation (NASDAQ: BRKRP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BRKRP stands at 9.3B. In comparison, RXST has a market cap of 188.6M. Regarding current trading prices, BRKRP is priced at $446.63 on the NASDAQ, while RXST trades at $4.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BRKRP currently has a P/E ratio of 244.34, whereas RXST's P/E ratio is -4.01. In terms of profitability, BRKRP's ROE is -0.05%, compared to RXST's ROE of -0.20%. Regarding short-term risk, BRKRP is less volatile compared to RXST. This indicates lower risk in terms of short-term price fluctuations for BRKRP.Check RXST's competition here
Xylo Technologies Ltd. (NASDAQ: MDGS)
BRKRP vs MDGS Comparison November 2026
Bruker Corporation (NASDAQ: BRKRP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BRKRP stands at 9.3B. In comparison, MDGS has a market cap of 178.9M. Regarding current trading prices, BRKRP is priced at $446.63 on the NASDAQ, while MDGS trades at $2.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BRKRP currently has a P/E ratio of 244.34, whereas MDGS's P/E ratio is -0.27. In terms of profitability, BRKRP's ROE is -0.05%, compared to MDGS's ROE of -0.51%. Regarding short-term risk, BRKRP is less volatile compared to MDGS. This indicates lower risk in terms of short-term price fluctuations for BRKRP.Check MDGS's competition here
Neuronetics, Inc. (NASDAQ: STIM)
BRKRP vs STIM Comparison November 2026
Bruker Corporation (NASDAQ: BRKRP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BRKRP stands at 9.3B. In comparison, STIM has a market cap of 163.4M. Regarding current trading prices, BRKRP is priced at $446.63 on the NASDAQ, while STIM trades at $2.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BRKRP currently has a P/E ratio of 244.34, whereas STIM's P/E ratio is -4.87. In terms of profitability, BRKRP's ROE is -0.05%, compared to STIM's ROE of -1.28%. Regarding short-term risk, BRKRP is less volatile compared to STIM. This indicates lower risk in terms of short-term price fluctuations for BRKRP.Check STIM's competition here
Quipt Home Medical Corp. (NASDAQ: QIPT)
BRKRP vs QIPT Comparison November 2026
Bruker Corporation (NASDAQ: BRKRP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BRKRP stands at 9.3B. In comparison, QIPT has a market cap of 162.3M. Regarding current trading prices, BRKRP is priced at $446.63 on the NASDAQ, while QIPT trades at $3.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BRKRP currently has a P/E ratio of 244.34, whereas QIPT's P/E ratio is -15.87. In terms of profitability, BRKRP's ROE is -0.05%, compared to QIPT's ROE of -0.08%. Regarding short-term risk, BRKRP is more volatile compared to QIPT. This indicates higher risk in terms of short-term price fluctuations for BRKRP.Check QIPT's competition here
Inogen, Inc. (NASDAQ: INGN)
BRKRP vs INGN Comparison November 2026
Bruker Corporation (NASDAQ: BRKRP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BRKRP stands at 9.3B. In comparison, INGN has a market cap of 160M. Regarding current trading prices, BRKRP is priced at $446.63 on the NASDAQ, while INGN trades at $6.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BRKRP currently has a P/E ratio of 244.34, whereas INGN's P/E ratio is -6.63. In terms of profitability, BRKRP's ROE is -0.05%, compared to INGN's ROE of -0.20%. Regarding short-term risk, BRKRP is less volatile compared to INGN. This indicates lower risk in terms of short-term price fluctuations for BRKRP.Check INGN's competition here
Quanterix Corporation (NASDAQ: QTRX)
BRKRP vs QTRX Comparison November 2026
Bruker Corporation (NASDAQ: BRKRP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BRKRP stands at 9.3B. In comparison, QTRX has a market cap of 137.1M. Regarding current trading prices, BRKRP is priced at $446.63 on the NASDAQ, while QTRX trades at $2.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BRKRP currently has a P/E ratio of 244.34, whereas QTRX's P/E ratio is -1.14. In terms of profitability, BRKRP's ROE is -0.05%, compared to QTRX's ROE of -0.44%. Regarding short-term risk, BRKRP is less volatile compared to QTRX. This indicates lower risk in terms of short-term price fluctuations for BRKRP.Check QTRX's competition here
EDAP TMS S.A. American Depositary Shares (NASDAQ: FOCL)
BRKRP vs FOCL Comparison November 2026
Bruker Corporation (NASDAQ: BRKRP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BRKRP stands at 9.3B. In comparison, FOCL has a market cap of 125.9M. Regarding current trading prices, BRKRP is priced at $446.63 on the NASDAQ, while FOCL trades at $3.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BRKRP currently has a P/E ratio of 244.34, whereas FOCL's P/E ratio is -3.25. In terms of profitability, BRKRP's ROE is -0.05%, compared to FOCL's ROE of -2.41%. Regarding short-term risk, BRKRP is less volatile compared to FOCL. This indicates lower risk in terms of short-term price fluctuations for BRKRP.Check FOCL's competition here
Owlet, Inc. (NYSE: OWLT)
BRKRP vs OWLT Comparison November 2026
Bruker Corporation (NASDAQ: BRKRP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BRKRP stands at 9.3B. In comparison, OWLT has a market cap of 121.6M. Regarding current trading prices, BRKRP is priced at $446.63 on the NASDAQ, while OWLT trades at $4.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BRKRP currently has a P/E ratio of 244.34, whereas OWLT's P/E ratio is -29.71. In terms of profitability, BRKRP's ROE is -0.05%, compared to OWLT's ROE of -0.50%. Regarding short-term risk, BRKRP is less volatile compared to OWLT. This indicates lower risk in terms of short-term price fluctuations for BRKRP.Check OWLT's competition here
Pulmonx Corporation (NASDAQ: LUNG)
BRKRP vs LUNG Comparison November 2026
Bruker Corporation (NASDAQ: BRKRP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BRKRP stands at 9.3B. In comparison, LUNG has a market cap of 109.9M. Regarding current trading prices, BRKRP is priced at $446.63 on the NASDAQ, while LUNG trades at $2.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BRKRP currently has a P/E ratio of 244.34, whereas LUNG's P/E ratio is -2.53. In terms of profitability, BRKRP's ROE is -0.05%, compared to LUNG's ROE of -0.98%. Regarding short-term risk, BRKRP is less volatile compared to LUNG. This indicates lower risk in terms of short-term price fluctuations for BRKRP.Check LUNG's competition here
iCAD, Inc. (NASDAQ: ICAD)
BRKRP vs ICAD Comparison November 2026
Bruker Corporation (NASDAQ: BRKRP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BRKRP stands at 9.3B. In comparison, ICAD has a market cap of 106.3M. Regarding current trading prices, BRKRP is priced at $446.63 on the NASDAQ, while ICAD trades at $3.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BRKRP currently has a P/E ratio of 244.34, whereas ICAD's P/E ratio is -20.37. In terms of profitability, BRKRP's ROE is -0.05%, compared to ICAD's ROE of -0.18%. Regarding short-term risk, BRKRP is more volatile compared to ICAD. This indicates higher risk in terms of short-term price fluctuations for BRKRP.Check ICAD's competition here
Hancock Jaffe Laboratories (NASDAQ: HJLI)
BRKRP vs HJLI Comparison November 2026
Bruker Corporation (NASDAQ: BRKRP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BRKRP stands at 9.3B. In comparison, HJLI has a market cap of 98.3M. Regarding current trading prices, BRKRP is priced at $446.63 on the NASDAQ, while HJLI trades at $10.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BRKRP currently has a P/E ratio of 244.34, whereas HJLI's P/E ratio is N/A. In terms of profitability, BRKRP's ROE is -0.05%, compared to HJLI's ROE of -0.70%. Regarding short-term risk, BRKRP is less volatile compared to HJLI. This indicates lower risk in terms of short-term price fluctuations for BRKRP.Check HJLI's competition here
Perspective Therapeutics, Inc. (AMEX: CATX)
BRKRP vs CATX Comparison November 2026
Bruker Corporation (NASDAQ: BRKRP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BRKRP stands at 9.3B. In comparison, CATX has a market cap of 95.9M. Regarding current trading prices, BRKRP is priced at $446.63 on the NASDAQ, while CATX trades at $0.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BRKRP currently has a P/E ratio of 244.34, whereas CATX's P/E ratio is -0.63. In terms of profitability, BRKRP's ROE is -0.05%, compared to CATX's ROE of -0.42%. Regarding short-term risk, BRKRP is less volatile compared to CATX. This indicates lower risk in terms of short-term price fluctuations for BRKRP.Check CATX's competition here
Asensus Surgical, Inc. (AMEX: ASXC)
BRKRP vs ASXC Comparison November 2026
Bruker Corporation (NASDAQ: BRKRP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BRKRP stands at 9.3B. In comparison, ASXC has a market cap of 94.9M. Regarding current trading prices, BRKRP is priced at $446.63 on the NASDAQ, while ASXC trades at $0.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BRKRP currently has a P/E ratio of 244.34, whereas ASXC's P/E ratio is -1.12. In terms of profitability, BRKRP's ROE is -0.05%, compared to ASXC's ROE of -1.18%. Regarding short-term risk, BRKRP is more volatile compared to ASXC. This indicates higher risk in terms of short-term price fluctuations for BRKRP.Check ASXC's competition here